At the time, I had already finished my Bioengineering studies, but I was continuing them in the Medical Biology field. As for quite some time Biomapas has been stuck in my mind as a prestigious company in the life sciences industry, I would visit their website or social networks for the latest news from time to time.

This is also how I found out about the Biomapas Academy.

 

Why did you choose to become part of the Biomapas Academy?

Actually, it’s mostly because of one conversation that influenced my perspective towards career paths. I have a relative that has become a career consultant. So, at the end of my Medical Biology studies, I figured, why not have a conversation with her? And it turns out that the key takeaway for me was unexpected: I was not open-minded enough about the real-life application of my master’s degree. Now I can see that it was true, but at the time, it was a surprise. I thought that my degree would solely give me a license to work in clinical laboratories in hospitals, but that was not true.

I got convinced that it was time for me to broaden my horizons and look at all possible perspectives a life sciences background can bring. So, I could not resist applying to the Biomapas Academy when I saw the announcement.

 

What was the Biomapas Academy like?

It was great to see how well organized this educational project was and how much you could learn about the main three areas. The lecturers are real experts in their respective fields and share a lot of information. Furthermore, I was surprised by how eventful the field of drug safety can be – we do not see most of it in our daily lives.

What did you do after the Biomapas Academy?

Once I started going to the Academy, one thing led to another. I received an invitation to try myself out in the Pharmacovigilance department as an intern even before the end of the Academy itself. I didn’t doubt much about the offer as the pharmacovigilance field was the one that got my attention the most during the Academy course. You hear about clinical trials a bit more often than what happens after the products reach the market.

Halfway through my internship, the people management team reached out to me about an open position in the QPPV team. It was in an area that piqued my interest, so I decided to apply. After a few interviews, I got the great news that I got the position! The remaining few weeks of my internship were joyful, knowing that I would continue as an employee.

 

So, what is your role in Biomapas?

Currently, I am an assistant in the QPPV team, which operates in a wide range of various analytical tasks related to drug safety on a global scale. The acronym QPPV stands for a specific legally obliged person who is personally responsible for the pharmacovigilance process of a particular drug. The team I am part of is full of highly skilled and experienced QPPVs who have become my career mentors and advisors. It also means that this is the right team to be in if I want to become a QPPV myself one day.

 

Any wishes to the future participants?

If you keep considering what career path might be the best for you, I advise you not to doubt and apply to the Biomapas Academy. You will at least gain a broad understanding of how the drug development process works, and it’s a great addition to your resume. If you are lucky, this might become a much greater experience than just an interesting set of lectures and assignments – it could potentially lead your future career too, just like it happened to me.

From the moment I entered Biomapas, it has exceeded my expectations so far. Besides the ability to analyze medical information, I like that many other qualities are helpful in the job: from my natural proactivity to language skills. Even the sales background gained in several part-time jobs during studies reflects the versatile, client-oriented atmosphere here at work. So Biomapas is a place where all – my life science education, experience, personality, and skills – found a home, and Biomapas Academy was the project which led to finding that home.

We can never be sure of where life will bring us. And this is a fun, risk-free way to try the industry out and see if it’s the right fit for you.

Biomapas Academy

What is Clinical Research? Regulatory Affairs? Pharmacovigilance?

The CIS Region: Excellent Potential for Patient Recruitment but is there any Risk to Quality?

The CIS Region: Excellent Potential for Patient Recruitment but is there any Risk to Quality?

The number of clinical trials worldwide is increasing more than 10% each year due to the new diseases, further research for better health products and development of new drugs. Though, for a successful clinical trial, there is a major challenge – patient recruitment, which is essential and the most challenging factor due to the increasing number of new clinical trials. In order to achieve the required patient recruitment, sponsors are looking for different solutions.

read more
The Predicted Impact of the ISO IDMP Standards Implementation Process Carried Out by the European Medicines Agency

The Predicted Impact of the ISO IDMP Standards Implementation Process Carried Out by the European Medicines Agency

The IDMP is a general term by which the 5 ISO data standards are referenced: ISO 11615 (regulated medicinal product information), ISO 11616 (regulated pharmaceutical product information), ISO 11238 (substances), ISO 11239 (pharmaceutical dose forms, units of presentation, routes of administration and packaging) and ISO 11240 (units of measurement). – which are being refined and implemented by regulatory bodies.

read more
Running a clinical trial in the Baltic states

Running a clinical trial in the Baltic states

In the past five years, an average of 175 clinical trials are being initiated in the Baltic states each year. An average of 64,8% of the population in the Baltic states are in the age from 15 to 65 years old, the main target audience for clinical trials. Furthermore, a large pool of treatment-naïve subjects is available compared to other EU countries or the US. Patients with special therapeutic diseases are transferred to the main central hospitals.

read more
Falsified Medicines Directive Implementation – Marketing Authorization Holder Perspective

Falsified Medicines Directive Implementation – Marketing Authorization Holder Perspective

Falsified Medicines Directive (FMD) 2011/62/EU which aims to increase the security of manufacturing and delivery of medicines across Europe as well as protect patients and prevent falsified medicines from entering the supply chain has come in force Feb 9th, 2019. With the first quarter almost over, it is a great opportunity to look back and share the experience. The new requirements for safety features to appear on the packaging of all prescription medicines.

read more
Biomapas appoints Chief Financial Officer

Biomapas appoints Chief Financial Officer

Filip Risteski was recently appointed as Chief Financial Officer (CFO) at Biomapas and will be one of the key players further strengthening continued growth of Biomapas. Filip will report directly to Audrius Sveikata, Biomapas Chief Executive Officer. As a CFO he will be responsible for placing control over finance function and financial strategy, by maximizing efficiency and ensuring highest quality standards. Furthermore, Filip will work with a management team on implementation of overall company business strategy.

read more
Remaining Vigilant and Compliant after Brexit: What’s next? (Latest Updates)

Remaining Vigilant and Compliant after Brexit: What’s next? (Latest Updates)

On 29th March 2017 UK submitted the notification of its intention to withdraw from the EU. This means that UK will become a ‘third country’ from 30th March’19. Even though leaving the EU with a deal remains the Government’s top priority, UK drug agency is publishing a series of guidance documents for industry and other stakeholders covering the proposed arrangements for the regulation of medicines, medical devices and clinical trials, if UK leaves EU with no deal.

read more
Implementation of ISO 9001 and 13485 standards: what does it bring to company and clients?

Implementation of ISO 9001 and 13485 standards: what does it bring to company and clients?

Compliance with high quality standards is a non-negotiable performance parameter in Pharmaceutical and Medical Device industries. During 2016, Biomapas was re-certified according to the newest ISO 9001 standard version. Moreover, at the beginning of 2017, ISO 13485 implementation into BIOMAPAS Quality Management System was initiated. We discussed the influence of current changes to the whole company and its quality management with Egidija Pauriene, MD, Quality Assurance Director.

read more
Changing regulatory environment: eCTD submissions to become obligatory as of 2018

Changing regulatory environment: eCTD submissions to become obligatory as of 2018

A new challenge is about to be faced by the MAHs of medicinal products. Since online tools are becoming a bigger part of our daily lives, the competent authorities are also moving forward step by step. 1st Jan 2018, the European Medicines Agency will require that all regulatory submissions for medicinal products authorized via Decentralized or Mutual Recognition Procedure will be provided in eCTD format.

read more
Tuberculosis Medicines Clinical Development in Eastern Europe and CIS

Tuberculosis Medicines Clinical Development in Eastern Europe and CIS

World Tuberculosis Day is commemorated every year on 24th March to raise awareness of tuberculosis, which is still causing death of nearly 1.5 million people each year, mostly in developing countries. It marks the day in 1882, when Dr. Robert Koch announced that he had discovered the cause of tuberculosis, the TB bacillus. In comparison to other infectious diseases caused by a single infectious agent, tuberculosis is the second biggest killer worldwide.

read more

Biomapas announces the opening of a new office in Sweden

Biomapas has recently announced the opening of a new office in Stockholm, Sweden. This new location strengthens Biomapas’ presence in the Nordic countries and further accommodates the rapid growth of the company.

The expansion into the Nordics is in direct response to demand from Biomapas clients seeking local Regulatory and Pharmacovigilance support. The company already has offices in Switzerland, Lithuania, Russia, Georgia and Ukraine.

read more

Big Enough To Cover  All Your Needs. Small Enough To Care.

Discover the tailored solutions that Biomapas provides to accelerate your clinical trials and optimize your drug development process.

Clinical Research

Regulatory Affairs

Pharmacovigilance

Medical Information